FDA Approves Ogsiveo for Desmoid Tumors

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Nov. 29, 2023 -- The U.S. Food and Drug Administration has approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.

The Fast Track and Breakthrough Therapy-designated approval was based on results from an international, multicenter trial in which 142 adult patients with progressing desmoid tumors not amenable to surgery were randomly assigned to receive 150 mg of Ogsiveo or placebo orally twice a day.

Results from the trial showed clinically meaningful and statistically significant improvement in progression-free survival for Ogsiveo compared with placebo. There was also a statistically significant benefit seen for Ogsiveo in the objective response rate (41 versus 8 percent). Additional benefit was seen for patient-reported pain favoring the Ogsiveo arm.

"Desmoid tumors are rare tumors that can lead to severe pain and disability," Richard Pazdur, M.D., director of the FDA Oncology Center of Excellence, said in a statement. "Today's approval will offer the first approved treatment option for patients beyond surgery and radiation."

Approval of Ogsiveo was granted to SpringWorks Therapeutics Inc.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-11-30 06:33

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords